Axsome Therapeutics (AXSM) Total Current Liabilities (2015 - 2026)

Axsome Therapeutics' Total Current Liabilities history runs 12 years deep, the most recent figure standing at $439.2 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 80.07% year-over-year to $439.2 million; the TTM figure through Mar 2026 stood at $439.2 million (up 80.07% YoY), while the FY2025 annual figure was $378.8 million, up 64.64% from the prior year.
• Total Current Liabilities came in at $439.2 million for Q1 2026 at Axsome Therapeutics, up from $378.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $439.2 million in Q1 2026 to a low of $24.5 million in Q1 2022.
• A 5-year average of $189.1 million and a median of $144.0 million in 2024 frame the typical range for Total Current Liabilities.
• On a YoY basis, Total Current Liabilities climbed as much as 318.64% in 2022 and fell as far as 13.22% in 2022.
• Axsome Therapeutics' Total Current Liabilities stood at $96.6 million in 2022, then surged by 43.8% to $138.9 million in 2023, then surged by 65.72% to $230.1 million in 2024, then soared by 64.64% to $378.8 million in 2025, then advanced by 15.94% to $439.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $439.2 million, $378.8 million, and $360.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison